Search

Background Sarcopenia is a condition characterized by decreased skeletal muscle mass due to physiological ageing or to a concomitant disease such as neoplasia. In cancer patients, a low lean body mass is suggested to be a negative prognostic factor for survival and for the development of dose-limiting chemotherapy toxicities irrespective of disease stage. Aim To evaluate the prognostic role of sarcopenia in patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy. Methods Our retrospective analysis included 56 mCRC patients who received first-line chemotherapy from 2014 to 2017 at the Medical Oncology Unit of our hospital. Computerized scans were performed before starting chemotherapy and at the first disease reassessment. Sarcopenia was assessed using the skeletal mass index = muscle area in cm2/(height in m2) calculated at the L3 vertebra. Overall survival and objective response rate were evaluated. Toxicities were analyzed during the first four cycles of therapy and graded according to Common Terminology Criteria for Adverse Events version 4.0. A loss of skeletal muscle mass ≥ 5% was considered indicative of deterioration in muscle condition. Results Median age was 67 years and 35.7% of patients were ≥ 70 years old. Fourteen patients (25%) were sarcopenic at baseline computed tomography (CT) scan (7/33 men; 7/23 women); 5/14 sarcopenic patients were ≥ 70 years old. Median follow-up was 26.8 mo (3.8-66.8 mo) and median overall survival was 27.2 mo (95%CI: 23.3-37.3). Sarcopenia was not correlated to overall survival (P = 0.362), to higher toxicities reported during the first 4 cycles of chemotherapy (P = 1.0) or to response to treatment (P = 0.221). At the first disease reassessment, a skeletal muscle loss (SML) ≥ 5% was found in 17 patients (30.3%) 3 of whom were already sarcopenic at baseline CT scan, while 7 patients became sarcopenic. SML was not correlated to overall survival (P = 0.961). No statistically significant correlation was found between baseline sarcopenia and age (P = 1.0), body mass index (P = 0.728), stage at diagnosis (P = 0.355) or neutrophil/lymphocyte ratio (P = 0.751). Conclusion Neither baseline sarcopenia nor SML affected survival. In addition, baseline sarcopenia was not related to worse treatment toxicity. However, these results must be interpreted with caution due to the limited sample size.

Periods of absence from supervised group exercise while maintaining physical activity might be a frequent pattern in adults' exercise habits. The aim of the present study was to determine detraining effects on musculoskeletal outcomes after a 3-month detraining period in early post-menopausal, osteopenic women. Due to the COVID-19 pandemic, we terminated the 18-month randomized controlled ACTLIFE exercise intervention immediately after the 13-month follow-up assessment. This put an abrupt stop to the high-intensity aerobic and resistance group exercise sessions undertaken three times per week by the exercise group (EG: n = 27) and the gentle exercise program performed once per week for the attention control group (CG: n = 27); but both groups were permitted to conduct individual outdoor activity for the 3-month lock-down period. Study endpoints were lean body mass (LBM), bone mineral density (BMD) at the lumbar spine (LS), maximum hip-/leg extension strength and power. Detraining-induced reductions of LBM, hip/leg strength and power (but not BMD-LS) were significantly greater (p p = 0.044) compared with the CG. Significant exercise effects, i.e. differences between EG and CG, present after 13 months of exercise, were lost after 3 months of detraining for LBM (p = 0.157) and BMD-LS (p = 0.065), but not for strength (p p Trial registration number: ClinicalTrials.gov: NCT04420806, 06.05.2020.

The aim of this study was to compare male vs. female athletes in strength and power performance relative to body mass (BM) and lean body mass (LBM) and to investigate the relationships between muscle architecture and strength in both genders. Sixteen men (age = 26.4 ± 5.0 y, body mass = 88.9 ± 16.6 kg, height = 177.6 ± 9.3 cm) and fourteen women (age = 25.1 ± 3.2 y, body mass = 58.1 ± 9.1 kg, height = 161.7 ± 4.8 cm) were tested for body composition and muscle thickness (MT) of vastus lateralis muscle (VT), pectoralis major (PEC), and trapezius (TRAP). In addition, participants were tested for lower body power at countermovement jump (CMJP) and upper-body power at bench press throw (BPT). Participants were also assessed for one repetition maximum (1RM) at bench press (1RMBP), deadlift (1RMDE), and squat (1RMSQ). Significantly greater (p &lt, 0.01) MT of the VL, PEC and TRAP muscles and LBM were detected in men compared to women. Significantly greater (p &lt, 0.05) 1RMBP and BPT adjusted for LBM were detected in men than in women. No significant gender differences after adjusting for LBM were detected for 1RMSQ (p = 0.945), 1RMDE (p = 0.472) and CMJP (p = 0.656). Significantly greater (p &lt, 0.05) results in all performance assessments adjusted for MT of the specific muscles, were detected in males compared to females. Superior performances adjusted for MT and LBM in men compared to women, may be related to gender differences in muscle morphology and LBM distribution, respectively.